We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

4 hedge funds and large institutions have $411K invested in Loncar China BioPharma ETF in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

813% more capital invested

Capital invested by funds: $45K → $411K (+$366K)

33% more funds holding

Funds holding: 3 → 4 (+1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$478K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$9.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
$386K +$478K +26,911 New
UBS Group
2
UBS Group
Switzerland
$16K -$9.1K -512 -32%
BBPWM
3
Blue Bell Private Wealth Management
Pennsylvania
$6K – – –
Morgan Stanley
4
Morgan Stanley
New York
$3K – – –

CHNA Hedge Fund Activity: Q3 2022 in Review

4 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2022, worth a combined $411K — up 813% from $45K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new CHNA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $478K. The largest seller was UBS Group, cutting an estimated $9.1K.

  • 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2022, up from 3 in Q2 2022.
  • Funds reported $411K of Loncar China BioPharma ETF stock for Q3 2022, up 813% quarter-over-quarter.
  • 1 fund opened new Loncar China BioPharma ETF positions in Q3 2022 and 0 closed out, a net change of +1 holder.
  • The largest Loncar China BioPharma ETF buyer in Q3 2022 was Jane Street, an estimated $478K added.
  • The largest Loncar China BioPharma ETF seller in Q3 2022 was UBS Group, an estimated $9.1K sold.

Based on aggregated 13F filings for Q3 2022.